Lazertinib-YH25448-DataSheet-生命科学试剂-MedChemExpress

1、Hotline: 400-820-3792Inhibitors Agonists Screening Librarieswww.MedChemELazertinibCat. No.: HY-109061CAS No.: 1903008-80-9Synonyms: YH25448; GNS-1480分式: CHNO分量: 554.64作靶点: EGFR作通路: JAK/STAT Signaling; Protein Tyrosine Kinase/RTK储存式: Powder -20C 3 years4C 2 yearsIn solvent -80C 6 months-20C 1 month溶解

2、性数据体外实验 DMSO : 9 mg/mL (16.23 mM; Need ultrasonic)Mass Solvent1 mg 5 mg 10 mg Concentration制备储备液1 mM 1.8030 mL 9.0149 mL 18.0297 mL5 mM 0.3606 mL 1.8030 mL 3.6059 mL10 mM 0.1803 mL 0.9015 mL 1.8030 mL请根据产品在不同溶剂中的溶解度，选择合适的溶剂配制储备液，并请注意储备液的保存式和期限。体内实验请根据您的实验动物和给药式选择适当的溶解案，配制前请先配制澄清的储备液，再依次添加助溶剂(为保证实验结果

3、的可靠性，体内实验的作液，建议您现现配，当天使；澄清的储备液可以根据储存条件，适当保存；以下溶剂前的百分 指该溶剂在您配制终溶液中的体积占)：1. 请依序添加每种溶剂： 10% DMSO 40% PEG300 5% Tween-80 45% salineSolubility: 0.9 mg/mL (1.62 mM); Clear solution2. 请依序添加每种溶剂： 10% DMSO 90% (20% SBE-CD in saline)Solubility: 0.9 mg/mL (1.62 mM); Clear solution3. 请依序添加每种溶剂： 10% DMSO 90% cor

4、n oil1/2 Master of Small Molecules 您边的抑制剂师www.MedChemESolubility: 0.9 mg/mL (1.62 mM); Clear solutionBIOLOGICAL ACTIVITY物活性 Lazertinib种有效，可逆，可服，可透过脑屏障的，突变体选择性的第三代 EGFR 酪氨酸激酶抑制剂，可于细胞肺癌的研究。IC50 & Target EGFRT790M体外研究 Lazertinib (YH25448) is a potent, highly mutant-selective, blood-brain barrier permea

5、ble, orally available andirreversible third-generation EGFR tyrosine kinase inhibitor, and can be used in the research of non-small celllung cancer. Lazertinib targets both T790M mutation and activating EGFR mutations (EGFRm) while sparingwild type 1.REFERENCES1. Byoung Chul Cho, et al. YH25448, a 3rd Generation EGFR-TKI, in Patients with EGFR-TKI-resistant NSCLC: Phase I/II Study Results.McePdfHeightCaution: Product has not been fully validated for medical applications.For research use only.Tel: 400-820-3792